GPC Biotech Signs Agreement with ICOS to Manufacture Antibodies for Clinical Studies
GPC Biotech has two antibody programs with a novel mechanism-of-action that are specific to MHC class II receptors. The fully human antibodies were both generated by MorphoSys from its HUCAL(r) libraries. GPC Biotech's oncology antibody program to treat MHC class II positive B-cell lymphomas is based on the finding that these antibodies specifically kill human lymphoma/leukemia cells, leaving normal resting cells unaffected. The induction of cell death which occurs rapidly upon binding of the antibody, does not require any additional immune system effector mechanisms. This is a potentially significant advantage compared to most other antibodies targeting B-cell lymphomas. The antibody developed in GPC Biotech's immunology program binds to MHC class II molecules and thereby prevents the initiation of undesired immune reactions, such as transplant rejection, rather than suppressing already existing immune reactions. For antibodies of both programs in vivo efficacy was announced in July of 2001.
Most read news
Topics
Organizations
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.